Management of Asymptomatic Lymphadenopathy
Introduction to Asymptomatic Lymphadenopathy
- Asymptomatic lymphadenopathy requires a careful approach to management, with consideration of the underlying cause, as recommended by the European Society for Medical Oncology (ESMO) and the American College of Radiology 1, 2
Observation and Monitoring
- For asymptomatic patients with follicular lymphoma, observation alone is recommended, with treatment initiated only upon occurrence of symptoms or signs due to lymphoma, as per the ESMO guidelines, which note no advantage in terms of overall survival for immediate treatment compared with observation 1
- Clinical reassessment for any new symptoms, including B symptoms, local symptoms, and signs of organ involvement, is necessary for patients under observation 1
- Node enlargement, defined as an increase by ≥3 mm from baseline, is a criterion for reevaluation 3
Imaging and Diagnostic Approaches
- Contrast-enhanced CT scans provide detailed anatomical information to differentiate between goiter and lymphadenopathy, assessing size, texture, density, and relationship to surrounding structures, as recommended by the American College of Radiology 2
- Ultrasound is the most established non-invasive imaging test for assessing axillary lymph nodes, allowing for detailed morphologic assessment and enabling ultrasound-guided biopsy if needed, with higher sensitivity and specificity than CT for characterizing axillary nodes, according to the American College of Radiology 4
- Consider PET-CT scan, particularly for nodes >15mm in short axis, to distinguish between benign and malignant etiologies and for staging if malignancy is suspected, as recommended by the European Respiratory Society and the American College of Chest Physicians 5, 6
- The American College of Chest Physicians recommends EBUS-TBNA as the preferred first diagnostic approach for paratracheal and mediastinal nodes, with high sensitivity and specificity for diagnosis 6
- For supraclavicular nodes, ultrasound-guided FNA is the preferred approach due to superficial location, as recommended by the American College of Radiology and other societies 7
Lymph Node Assessment
- Normal axillary lymph nodes typically have a short axis diameter ≤10 mm, preserved fatty hilum, smooth, well-defined borders, and uniform and homogeneous attenuation, according to the American College of Radiology 4, 2
- Features that raise concern for malignancy include a short axis diameter >10 mm, cortical thickness >3 mm, loss of fatty hilum, irregular or spiculated margins, and heterogeneous enhancement, as recommended by the American College of Radiology 4
- Size assessment using short axis measurement is the standard, with nodes ≤10 mm considered likely normal, 10-15 mm considered borderline, and >15 mm considered definitely enlarged 2
- Lymph nodes >15mm in short axis have a higher likelihood of pathologic significance, according to the American College of Radiology 2
Management of Specific Conditions
- For lung cancer with nodal metastasis, a complete staging workup, multidisciplinary tumor board discussion, and treatment based on stage are recommended 2
- For lymphoma, referral to hematology-oncology, additional workup, and treatment based on lymphoma subtype and stage are recommended 2
- For metastatic disease from extrathoracic primary, search for primary tumor site and treatment directed at primary malignancy are recommended 2
- For sarcoidosis, pulmonary function tests, evaluation for extrapulmonary involvement, and treatment if symptomatic or organ dysfunction present are recommended 2
- For tuberculosis, sputum cultures, anti-tuberculosis therapy (6-9 month regimen of INH, RIF, PZA, and EMB), and contact tracing are recommended, as recommended by the American Journal of Respiratory and Critical Care Medicine 8
Follow-up and Surveillance
- Close follow-up with repeat imaging in 3 months is recommended for patients with non-diagnostic initial workup, as recommended by the American College of Radiology 2
- For benign reactive lymphadenopathy, follow-up imaging in 3-6 months to ensure stability or resolution is recommended, as recommended by the American College of Radiology 2
- For patients with confirmed malignancy, follow-up according to disease-specific protocols is recommended 2